GENETIC ANALYSIS NK -60 Total Assets
GENETIC ANALYSIS NK -60 total assets. Based on the latest financial reports, GENETIC ANALYSIS NK -60 (8V8) holds total assets worth €44.64 Million EUR (≈ $52.19 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see GENETIC ANALYSIS NK -60 market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of GENETIC ANALYSIS NK -60 (2021–2025)
Total assets of GENETIC ANALYSIS NK -60 from 2021 to 2025. This chart illustrates how GENETIC ANALYSIS NK -60's total assets have evolved over time, based on quarterly financial data. See GENETIC ANALYSIS NK -60 stock price for real-time trading data and today's change.
GENETIC ANALYSIS NK -60 - Asset Composition Analysis
GENETIC ANALYSIS NK -60 Total Assets Breakdown (December 2025)
GENETIC ANALYSIS NK -60 total assets breakdown as of December 2025. GENETIC ANALYSIS NK -60's total assets of €44.64 Million consist of 59.3% current assets and 40.8% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 44.6% |
| Accounts Receivable | €1.91 Million | 3.6% |
| Inventory | €804.00K | 1.5% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €17.44 Million | 33.3% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how GENETIC ANALYSIS NK -60's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore GENETIC ANALYSIS NK -60 short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GENETIC ANALYSIS NK -60's current assets represent 59.3% of total assets in 2025, a decrease from 69.0% in 2021.
- Cash Position: Cash and equivalents constituted 44.6% of total assets in 2025, down from 55.1% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 33.0% of total assets, an increase from 29.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 33.3% of total assets.
GENETIC ANALYSIS NK -60 Competitors by Total Assets
Key competitors of GENETIC ANALYSIS NK -60 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Lonza Group AG
SW:LONN
|
Switzerland | CHF18.26 Billion |
|
Revvity Inc.
NYSE:RVTY
|
USA | $12.00 Billion |
|
Dr. Lal Path Labs Ltd.
NSE:LALPATHLAB
|
India | Rs31.46 Billion |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥9.20 Billion |
|
Cowealth Medical China Co.Ltd.
SHG:603122
|
China | CN¥1.42 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Prodia Widyahusada Tbk PT
JK:PRDA
|
Indonesia | Rp2.57 Trillion |
|
Scope Fluidics SA
WAR:SCP
|
Poland | zł141.67 Million |
GENETIC ANALYSIS NK -60 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.42 | 2.30 | 2.26 |
| Quick Ratio | 1.33 | 2.27 | 2.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €6.77 Million | €19.26 Million | €11.80 Million |
GENETIC ANALYSIS NK -60 - Advanced Valuation Insights
This section examines the relationship between GENETIC ANALYSIS NK -60's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.15 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | 23.8% |
| Total Assets | €52.45 Million |
| Market Capitalization | $2.36 Million USD |
Valuation Analysis
Below Book Valuation: The market values GENETIC ANALYSIS NK -60's assets below their book value (0.05x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: GENETIC ANALYSIS NK -60's assets grew by 23.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for GENETIC ANALYSIS NK -60 (2021–2025)
The table below shows the annual total assets of GENETIC ANALYSIS NK -60 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €52.45 Million ≈ $61.31 Million |
+23.76% |
| 2024-12-31 | €42.38 Million ≈ $49.54 Million |
-20.78% |
| 2023-12-31 | €53.49 Million ≈ $62.54 Million |
-16.97% |
| 2022-12-31 | €64.42 Million ≈ $75.32 Million |
-22.84% |
| 2021-12-31 | €83.49 Million ≈ $97.61 Million |
-- |
About GENETIC ANALYSIS NK -60
Genetic Analysis AS, a science-based diagnostic company, engages in the research, development, manufacturing, and sale of diagnostic test solutions for human microbiome in the United States, Europe, and internationally. The company offers GA-map MHI Gut Health Test, a microbiome-based diagnostic test for antibiotic-induced microbiome imbalances; GA-map Dysbiosis Test, a diagnostic microbiome test… Read more